900
Views
0
CrossRef citations to date
0
Altmetric
State-of-the-Art Review

Early diagnosis strategy of calciphylaxis in dialysis patients

&
Article: 2264407 | Received 25 Apr 2023, Accepted 23 Sep 2023, Published online: 05 Oct 2023

References

  • Nigwekar SU, Thadhani R, Brandenburg VM. Calciphylaxis. N Engl J Med. 2018;378(18):1–9. doi: 10.1056/NEJMra1505292.
  • Colboc H, Moguelet P, Bazin D, et al. Localization, morphologic features, and chemical composition of calciphylaxis-related skin deposits in patients with calcific uremic arteriolopathy. JAMA Dermatol. 2019;155(7):789–796. doi: 10.1001/jamadermatol.2019.0381.
  • Angelis M, Wong LL, Myers SA, et al. Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery. 1997;122(6):1083–1090. doi: 10.1016/s0039-6060(97)90212-9.
  • Nigwekar SU, Zhao S, Wenger J, et al. A nationally representative study of calcific uremic arteriolopathy risk factors. J Am Soc Nephrol. 2016;27(11):3421–3429. doi: 10.1681/ASN.2015091065.
  • Liu Y, Yang C, Yang X, et al. Prevalence and clinical characteristics of calciphylaxis in Chinese hemodialysis patients. Front Med. 2022;9:902171. doi: 10.3389/fmed.2022.902171.
  • McCarthy JT, El-Azhary RA, Patzelt MT, et al. Survival, risk factors, and effect of treatment in 101 patients with calciphylaxis. Mayo Clin Proc. 2016;91(10):1384–1394. doi: 10.1016/j.mayocp.2016.06.025.
  • Bonchak JG, Park KK, Vethanayagamony T, et al. Calciphylaxis: a case series and the role of radiology in diagnosis. Int J Dermatol. 2016;55(5):e275-279–e279. doi: 10.1111/ijd.13043.
  • Zhu X, Liu Y, Yang X, et al. Identifying subcutaneous tissue microcalcification by fluo-3 AM imaging in cutaneous calciphylaxis. Exp Dermatol. 2022;31(10):1632–1634. doi: 10.1111/exd.14579.
  • Mochel MC, Arakaki RY, Wang G, et al. Cutaneous calciphylaxis: a retrospective histopathologic evaluation. Am J Dermatopathol. 2013;35(5):582–586. doi: 10.1097/DAD.0b013e31827c7f5d.
  • García-Lozano JA, Ocampo-Candiani J, Martínez-Cabriales SA, et al. An update on calciphylaxis. Am J Clin Dermatol. 2018;19(4):599–608. doi: 10.1007/s40257-018-0361-x.
  • Ghosh T, Winchester DS, Davis MDP, et al. Early clinical presentations and progression of calciphylaxis. Int J Dermatol. 2017;56(8):856–861. doi: 10.1111/ijd.13622.
  • Liu Y, Zhang X, Xie X, et al. Risk factors for calciphylaxis in chinese hemodialysis patients: a matched case-control study. Ren Fail. 2021;43(1):406–416. doi: 10.1080/0886022X.2021.1884094.
  • Hayashi M, Takamatsu I, Kanno Y, et al. A case-control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant. 2012;27(4):1580–1584. doi: 10.1093/ndt/gfr658.
  • Gaisne R, Péré M, Menoyo V, et al. Calciphylaxis epidemiology, risk factors, treatment and survival among French chronic kidney disease patients: a case-control study. BMC Nephrol. 2020;21(1):63. doi: 10.1186/s12882-020-01722-y.
  • Lehman JS, Chen TY, Lohse CM, et al. Evaluating the validity of subclassifying warfarin-associated nonuremic calciphylaxis: a retrospective cohort study. Int J Dermatol. 2018;57(5):572–574. doi: 10.1111/ijd.13884.
  • Gabel CK, Nguyen ED, Chakrala T, et al. Assessment of outcomes of calciphylaxis. J Am Acad Dermatol. 2021;85(4):1057–1064. doi: 10.1016/j.jaad.2020.10.067.
  • Mizuiri S, Nishizawa Y, Yamashita K, et al. Relationship of matrix Gla protein and vitamin K with vascular calcification in hemodialysis patients. Ren Fail. 2019;41(1):770–777. doi: 10.1080/0886022X.2019.1650065.
  • Jeong HS, Dominguez AR. Calciphylaxis: controversies in pathogenesis, diagnosis and treatment. Am J Med Sci. 2016;351(2):217–227. doi: 10.1016/j.amjms.2015.11.015.
  • Sreedhar A, Sheikh HA, Scagliotti CJ, et al. Advanced-stage calciphylaxis: think before you punch. Cleve Clin J Med. 2016;83(8):562–564. doi: 10.3949/ccjm.83a.15103.
  • Nigwekar SU, Kroshinsky D, Nazarian RM, et al. Calciphylaxis: risk factors, diagnosis, and treatment. Am J Kidney Dis. 2015;66(1):133–146. doi: 10.1053/j.ajkd.2015.01.034.
  • El-Azhary RA, Patzelt MT, McBane RD, et al. Calciphylaxis: a disease of pannicular thrombosis. Mayo Clin Proc. 2016;91(10):1395–1402. doi: 10.1016/j.mayocp.2016.06.026.
  • Chiriac A, Grosu OM, Terinte C, et al. Calcific uremic arteriolopathy (calciphylaxis) calls into question the validity of guidelines of diagnosis and treatment. J Dermatolog Treat. 2020;31(5):545–548. doi: 10.1080/09546634.2019.1618435.
  • Kodumudi V, Jeha GM, Mydlo N, et al. Management of cutaneous calciphylaxis. Adv Ther. 2020;37(12):4797–4807. doi: 10.1007/s12325-020-01504-w.
  • Weenig RH, Sewell LD, Davis MD, et al. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol. 2007;56(4):569–579. doi: 10.1016/j.jaad.2006.08.065.
  • Davis JM. The relationship between obesity and calciphylaxis: a review of the literature. Ostomy/Wound Manage. 2016;62(1):12–18.
  • Yang CL, Liu YQ, Ni HF, et al. Potential effect of sodium thiosulfate in calciphylaxis: remission of intractable pain. J Pak Med Assoc. 2021;71(2):340–342.
  • Patecki M, Lehmann G, Brasen JH, et al. A case report of severe calciphylaxis - suggested approach for diagnosis and treatment. BMC Nephrol. 2017;18(1):137. doi: 10.1186/s12882-017-0556-z.
  • Mormile I, Mosella F, Turco P, et al. Calcinosis cutis and calciphylaxis in autoimmune connective tissue diseases. Vaccines. 2023;11(5):898. doi: 10.3390/vaccines11050898.
  • Byers A, Herrera N, Owoyemi I. Chronic inflammation and calciphylaxis. BMJ Case Rep. 2022;15(4):e248668. doi: 10.1136/bcr-2021-248668.
  • Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6(4):913–921. doi: 10.2215/CJN.06040710.
  • Chandran M, Wong J. Secondary and tertiary hyperparathyroidism in chronic kidney disease: an endocrine and renal perspective. Indian J Endocrinol Metab. 2019;23(4):391–399. doi: 10.4103/ijem.IJEM_292_19.
  • Nigwekar SU, Bloch DB, Nazarian RM, et al. Vitamin K-dependent carboxylation of matrix gla protein influences the risk of calciphylaxis. J Am Soc Nephrol. 2017;28(6):1717–1722. doi: 10.1681/ASN.2016060651.
  • Idris KM, Laing ME. Xeroradiography as a noninvasive tool in diagnosing calciphylaxis. JAMA Dermatol. 2022;158(9):1080–1082. doi: 10.1001/jamadermatol.2022.2158.
  • Shmidt E, Murthy NS, Knudsen JM, et al. Net-like pattern of calcification on plain soft-tissue radiographs in patients with calciphylaxis. J Am Acad Dermatol. 2012;67(6):1296–1301. doi: 10.1016/j.jaad.2012.05.037.
  • Yu Q, Liu Y, Xie X, et al. Radiomics-based method for diagnosis of calciphylaxis in patients with chronic kidney disease using computed tomography. Quant Imaging Med Surg. 2021;11(11):4617–4626. doi: 10.21037/qims-20-1211.
  • Zhang L, Li L, Feng G, et al. Advances in CT techniques in vascular calcification. Front Cardiovasc Med. 2021;8:716822. doi: 10.3389/fcvm.2021.716822.
  • Paul S, Rabito CA, Vedak P, et al. The role of bone scintigraphy in the diagnosis of calciphylaxis. JAMA Dermatol. 2017;153(1):101–103. doi: 10.1001/jamadermatol.2015.4591.
  • Martineau P, Pelletier-Galarneau M, Bazarjani S. The role of bone scintigraphy with single-photon emission computed tomography-computed tomography in the diagnosis and evaluation of calciphylaxis. World J Nucl Med. 2017;16(2):172–174. doi: 10.4103/1450-1147.203076.
  • Shi W, Xie X, Liu Y, et al. The mystery of black lungs in a patient with calciphylaxis. J Nephrol. 2021;34(5):1553–1555. doi: 10.1007/s40620-021-01121-y.
  • Itani M, Matesan M, Behnia S, et al. Calciphylaxis on bone scan: correlation between molecular and cross-sectional findings. Radiol Case Rep. 2017;12(1):175–178. doi: 10.1016/j.radcr.2016.11.027.
  • Raduka J, Aggarwal A, Johnson K, et al. Bone scintigraphy findings in calciphylaxis. Radiol Case Rep. 2018;13(2):315–319. doi: 10.1016/j.radcr.2017.12.005.
  • Peller PJ, Ho VB, Kransdorf MJ. Extraosseous Tc-99m MDP uptake: a pathophysiologic approach. Radiographics. 1993;13(4):715–734. doi: 10.1148/radiographics.13.4.8356264.
  • Hall DJ, Gentile LF, Duckworth LV, et al. Calciphylaxis of the breast: a case report and literature review. Breast J. 2016;22(5):568–572. doi: 10.1111/tbj.12632.
  • AlQattan AS, Ghulam WZ, Aldaoud N, et al. Breast fat necrosis secondary to warfarin-induced calciphylaxis, a rare mimicker of breast cancer: a case report and a review of literature. Breast J. 2021;27(3):258–263. doi: 10.1111/tbj.14160.
  • Tobarran N, Collin M. Point-of-care ultrasound in the diagnosis of calciphylaxis. Clin Pract Cases Emerg Med. 2020;4(3):495–496. doi: 10.5811/cpcem.2020.7.47886.
  • Pyle HJ, Shedd CM, Begovic J, et al. Complications and histopathological findings of image-guided core needle biopsy in diagnosis of cutaneous calciphylaxis. Am J Dermatopathol. 2023;45(6):414–417. doi: 10.1097/DAD.0000000000002426.
  • Chen TY, Lehman JS, Gibson LE, et al. Histopathology of calciphylaxis: cohort study with clinical correlations. Am J Dermatopathol. 2017;39(11):795–802. doi: 10.1097/DAD.0000000000000824.
  • Yu WY, Bhutani T, Kornik R, et al. Warfarin-associated nonuremic calciphylaxis. JAMA Dermatol. 2017;153(3):309–314. doi: 10.1001/jamadermatol.2016.4821.
  • Mask-Bull L, Lee MP, Wang A. Image-guided core-needle biopsy for the diagnosis of cutaneous calciphylaxis. JAMA Dermatol. 2019;155(7):856–857. doi: 10.1001/jamadermatol.2019.0413.
  • Dobry AS, Nguyen ED, Shah R, et al. The role of skin biopsy in diagnosis and management of calciphylaxis: a retrospective analysis. J Am Acad Dermatol. 2021;85(3):765–767. doi: 10.1016/j.jaad.2020.05.101.
  • Rotondi S, De Martini N, Tartaglione L, et al. On the role of skin biopsy in the diagnosis of calcific uremic arteriolopathy: a case-based discussion. J Nephrol. 2020;33(4):859–865. doi: 10.1007/s40620-019-00678-z.
  • Magro CM, Simman R, Jackson S. Calciphylaxis: a review. J Am Col Certif Wound Spec. 2010;2(4):66–72. doi: 10.1016/j.jcws.2011.03.001.
  • Musso CG, Enz PA, Kowalczuk A, et al. Differential diagnosis of calciphylaxis in chronic dialysis patients. Int Urol Nephrol. 2020;52(3):595–597. doi: 10.1007/s11255-020-02388-z.
  • Ng AT, Peng DH. Calciphylaxis. Dermatol Ther. 2011;24(2):256–262. doi: 10.1111/j.1529-8019.2011.01401.x.
  • Liu Y, Xie X, Zhang X. Diagnosis strategy of calciphylaxis in dialysis patients. Chin J Nephrol. 2022;38(6):561–566.
  • Hayashi M. Calciphylaxis: diagnosis and clinical features. Clin Exp Nephrol. 2013;17(4):498–503. doi: 10.1007/s10157-013-0782-z.
  • Jiao Y, Sun L, Xie X, et al. Clinical features and outcomes of calciphylaxis in chinese patients with chronic kidney disease. Nephrology. 2023;28(6):305–314. doi: 10.1111/nep.14156.
  • Yang X, Liu Y, Xie X, et al. Use of the optimized sodium thiosulfate regimen for the treatment of calciphylaxis in Chinese patients. Ren Fail. 2022;44(1):914–922. doi: 10.1080/0886022X.2022.2081179.
  • Liu ZH, Yu XQ, Yang JW, et al. Prevalence and risk factors for vascular calcification in Chinese patients receiving dialysis: baseline results from a prospective cohort study. Curr Med Res Opin. 2018;34(8):1491–1500. doi: 10.1080/03007995.2018.1467886.
  • Vallabhajosyula S, Said SM, Kitzmann AS, et al. Accelerated extensive mitral valve calcification in a young end-stage kidney disease patient. Eur Heart J. 2020;41(45):4361–4361. doi: 10.1093/eurheartj/ehaa715.
  • Generali JA, Cada DJ. Sodium thiosulfate: calciphylaxis. Hosp Pharm. 2015;50(11):975–977. doi: 10.1310/hpj5011-975.